Debiopharm Group™ (Debiopharm) and Ascepion Pharmaceuticals, Inc. (Ascepion) have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.
ASP-08126 is a potent orally available small molecule that binds and inhibits several tyrosine kinase oncogenes implicated in many aspects of cancer development including tumour growth, metastasis, and tumour angiogenesis.
ASP-08126 is expected to be effective in the treatment of various solid tumours as a mono-therapeutic agent or in combination with other anti-cancer therapies.
“The potential of Debio 1144 to simultaneously inhibit many aspects of cancer development is making that substance extremely attractive to Debiopharm”, said Rolland-Yves Mauvernay, President and founder of Debiopharm, who added “Debio 1144 has the potential of helping patients suffering from several tumour types. Due to its inhibition profile Debio 1144, is expected to lead to high anti-tumour efficacy”.
“We are very pleased to collaborate with Debiopharm, a company with track records and expertise in the development of cancer medicines, to develop our innovative cancer therapeutics. The formation of this partnership will facilitate the development of ASP-08126 and benefit cancer patients ultimately”, stated Dr. Shan Jiang, President and CEO of Ascepion Pharmaceuticals.